| Summary: | The toxicokinetics (TK) of hydrolyzed fumonisin B<sub>1</sub> (HFB<sub>1</sub>) were evaluated in 16 broiler chickens after being fed either a control or a fumonisins-contaminated diet (10.8 mg fumonisin B<sub>1</sub>, 3.3 mg B<sub>2</sub> and 1.5 mg B<sub>3</sub>/kg feed) for two weeks, followed by a single oral (PO) or intravenous (IV) dose of 1.25 mg/kg bodyweight (BW) of HFB<sub>1</sub>. Fumonisin B<sub>1</sub> (FB<sub>1</sub>), its partially hydrolyzed metabolites pHFB<sub>1a</sub> and pHFB<sub>1b</sub>, and fully hydrolyzed metabolite HFB<sub>1</sub>, were determined in chicken plasma using a validated ultra-performance liquid chromatography–tandem mass spectrometry method. None of the broiler chicken showed clinical symptoms of fumonisins (FBs) or HFB<sub>1</sub> toxicity during the trial, nor was an aberration in body weight observed between the animals fed the FBs-contaminated diet and those fed the control diet. HFB<sub>1</sub> was shown to follow a two-compartmental pharmacokinetic model with first order elimination in broiler chickens after IV administration. Toxicokinetic parameters of HFB<sub>1</sub> demonstrated a total body clearance of 16.39 L/kg·h and an intercompartmental flow of 8.34 L/kg·h. Low levels of FB<sub>1</sub> and traces of pHFB<sub>1b</sub> were found in plasma of chickens fed the FBs-contaminated diet. Due to plasma concentrations being under the limit of quantification (LOQ) after oral administration of HFB<sub>1</sub>, no toxicokinetic modelling could be performed in broiler chickens after oral administration of HFB<sub>1</sub>. Moreover, no phase II metabolites, nor N-acyl-metabolites of HFB<sub>1</sub> could be detected in this study.
|
|---|